Mobidiag is a Molecular diagnostic company developing and commercializing solutions for the detection of infectious diseases.
Mobidiag is a commercial stage, fast-growing Finnish-French biotechnology company that develops and markets innovative molecular diagnostic solutions for gastrointestinal infections, antimicrobial resistance management, healthcare associated infections (HAIs), respiratory infections and sepsis. Based on well-established qPCR and microarray technologies, Mobidiag offers a broad range of tests and automated platforms. These include a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases adapted to laboratories of all sizes. They allow detection of most clinically relevant bacteria, parasites, viruses and markers for antibiotic resistance.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 14, 2019 | Debt Financing | €25M | 1 | European Investment Bank | — | Detail |
Nov 15, 2018 | Debt Financing | €4M | 1 | European Investment Bank | — | Detail |
Jul 18, 2016 | Debt Financing | $16.50M | 1 | European Investment Bank | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Debt Financing |